From Joe Burnett, President & CEO:
The first few months of 2021 have been exciting for the ClearPoint team. First, we announced two impactful partnerships: one with global health technology leader Philips to license and commercialize the ClearPoint Maestro™ Brain Model with applications across drug delivery, DBS and LiTT, as well as with Utah-based Blackrock MicroSystems to co-develop its Microelectric Recording platform for use both in the MRI suite and Operating Room. Second, we supported our partner PTC Therapeutics for the first early access gene therapy cases in France to treat the rare pediatric genetic disorder AADC Deficiency. Third, we installed our first system in Denmark where we deployed our 2.0 software version for the first time in Europe. And finally, we expanded our Biologics and Drug Delivery team to better serve the translational needs of our gene and stem cell partners and drive consistent results from bench to bedside.
Our goal throughout the last 12 months was to exit the COVID-19 pandemic in a better position than we started. Despite still dealing with COVID-related case postponements, we believe our strategy, pipeline of partners, and portfolio are more resilient than ever. Last month we led a significant capital raise for the company to ensure we have a strong balance sheet to weather future storms that come our way. Adding this new funding will also allow our talented team to relentlessly execute on our strategy and help speed the introduction of new innovations to neurosurgeons and their patients in the United States, Europe and beyond.
We are grateful to our loyal customers, partners and teammates after a year that has taken such a large toll on families and businesses around the globe. We look forward to continuing to partner with you to drive neurosurgical innovation, whether it be in the pre-clinical setting, the MRI suite, or the OR. If you have any questions about the company or our strategy, please reach out to me personally.
In February 2021 we announced a worldwide license and research agreement with Philips, a global leader in health technology, to commercialize the ClearPoint ‘Maestro’ Brain Model. We expect the first-generation anatomical segment analysis tool to be launched in 2022. Click Here to Learn More
We are delighted to report the first use of our ClearPoint 2.0 Software in Europe at Rigshospitalet in Copenhagen, Denmark. Rigshospitalet is also the first European site to use the ClearPoint Neuro Navigation System under live MRI guidance for navigation of a laser catheter in the brain. Click Here to Read More
ClearPoint Neuro's partnership with Blackrock Microsystems empowers ClearPoint to compete in new and complementary markets with differentiated and innovative products, representing an estimated combined addressable market of over $100 million. Click Here to Learn More
Ernesto Salegio, PhD Joins the ClearPoint Team as Vice President, Segment Leader Translational & Pre-Clinical Research
Our newest addition, Ernesto Salegio, PhD, leads our expanding pre-clinical and translational development team to support gene and stem cell therapy partners. Click Here to Learn More
CHU-Montpellier Utilizes ClearPoint Technology to Treat First Two European AADC Deficiency Patients Under France's Early Access Program
The ClearPoint Neuro congratulates our partner PTC Therapeutics on the treatment of the first two European AADC Deficiency patients under France’s innovative Early Access Program (ex-ATU). The patients were treated at Montpellier University Hospital Center using ClearPoint technology in December 2020 and February 2021. Click Here to Read More